Google's secretive Calico signed yet another partnership with a world-class research outfit, this time divulging some details that could provide clues on how it plans to attack aging.
Google's Calico has been looking for a mix of clinical-stage development programs and promising scientific exploration that can be translated into new therapies. Today it pulled back the wraps from a partnership it formed with UC San Francisco's acclaimed Peter Walter, whose lab has been working on the ways cells function while under stress.
Johnson & Johnson and Google have partnered to create new robotic-assisted surgical platforms. The deal is the latest example of Google working with a major life sciences company to make a significant technological advance.
Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out its R&D mission.
The Financial Times has taken a look at the implications of Apple and Google's ever-growing interest in healthcare and life sciences.
Slowly but surely, Google's star-driven biotech Calico is laying the foundation for what promises to be a major biotech focused on some of the biggest diseases that limit longevity. There's a Big Pharma partnership with AbbVie, a development deal down in Texas and now it's time to team up with top scientists. Earlier in the week Harvard and MIT's renowned Broad Institute signed on to work with Calico on pushing new therapies into the clinic.
Google has added another publicly available database to its growing Genomics platform. The latest deal sees Google Genomics host Tute Genomics' repository of 8.5 billion annotations of genetic variants, giving users another resource to probe with the tech giant's growing arsenal of data integration tools.
Google has given the world a peek at one of the ways in which it thinks algorithms and huge datasets could reshape drug discovery. The work involves trying to make virtual drug screening more efficient using the same ethos Google applies to most problems: More data, more computing power.
The FDA made its first move into the world of smartphone apps this week with a tool to allow users of iOS and Android devices to view information on drug shortages. And the reception to the app was broadly positive, with users praising the tool itself and the FDA for pushing into the mobile sector.
Google is developing a wearable medical device consisting of a magnet that would collect ingested nanoparticles whose job it is to attach to cancerous cells and take them to the magnet. The nanoparticles convey data to the magnet by "lighting up" cancer cells, Andrew Conrad, the head of Google's life sciences unit, said.